MA50174A - Formules de protéines de fusion vegfr-fc - Google Patents

Formules de protéines de fusion vegfr-fc

Info

Publication number
MA50174A
MA50174A MA050174A MA50174A MA50174A MA 50174 A MA50174 A MA 50174A MA 050174 A MA050174 A MA 050174A MA 50174 A MA50174 A MA 50174A MA 50174 A MA50174 A MA 50174A
Authority
MA
Morocco
Prior art keywords
vegfr
fusion protein
protein formulas
formulas
fusion
Prior art date
Application number
MA050174A
Other languages
English (en)
Inventor
Robert Matthew Fesinmeyer
Monica Michelle Goss
Sekhar Kanapuram
Rahul Rajan Kaushik
Sai Chakradhar Padala
Yael Wexler-Cohen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA50174A publication Critical patent/MA50174A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA050174A 2017-09-18 2018-09-17 Formules de protéines de fusion vegfr-fc MA50174A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559987P 2017-09-18 2017-09-18
US201862618910P 2018-01-18 2018-01-18

Publications (1)

Publication Number Publication Date
MA50174A true MA50174A (fr) 2020-07-29

Family

ID=63794648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050174A MA50174A (fr) 2017-09-18 2018-09-17 Formules de protéines de fusion vegfr-fc

Country Status (4)

Country Link
US (3) US20200255496A1 (fr)
EP (1) EP3684332A1 (fr)
MA (1) MA50174A (fr)
WO (1) WO2019055902A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101861163B1 (ko) * 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
MX2020005170A (es) 2017-11-17 2020-10-16 Amgen Inc Formulaciones de proteinas de fusion vegfr-fc.
EP4495136A3 (fr) 2018-01-26 2025-04-23 The Regents of the University of California Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf
EP3761953A1 (fr) * 2018-03-08 2021-01-13 Coherus Biosciences, Inc. Formulations aqueuses stables d'aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
SG11202010684YA (en) * 2018-05-10 2020-11-27 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
US20240166718A1 (en) * 2021-02-17 2024-05-23 Arecor Limited Aqueous composition of an engineered protein construct comprising an fc domain
TWI831202B (zh) * 2022-05-13 2024-02-01 新源生物科技股份有限公司 血管內皮生長因子受體融合蛋白醫藥組合物
TWI892441B (zh) * 2022-05-13 2025-08-01 新源生物科技股份有限公司 血管內皮生長因子受體融合蛋白醫藥組合物
WO2025240630A1 (fr) * 2024-05-14 2025-11-20 Abbott Laboratories Compositions de réactifs pour l'amplification isotherme d'acides nucléiques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
BRPI0707796A2 (pt) * 2006-02-15 2011-05-10 Imclone Systems Inc formulaÇço, e, mÉtodo de tratamento
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP3753548A1 (fr) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Formulations antagonistes vegf appropriées pour l'administration intravitréenne
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
AU2017213103B2 (en) 2016-01-26 2022-08-11 Formycon Ag Liquid formulation of a VEGF antagonist
EP3541365A1 (fr) 2016-11-21 2019-09-25 Just Biotherapeutics, Inc. Formulations d'aflibercecept et leurs utilisations

Also Published As

Publication number Publication date
US20240409611A1 (en) 2024-12-12
EP3684332A1 (fr) 2020-07-29
WO2019055902A1 (fr) 2019-03-21
US20200255496A1 (en) 2020-08-13
US20230025418A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
EP3880814A4 (fr) Protéine de fusion
DK3583125T3 (da) Albuminbindende domænefusionsproteiner
MA50174A (fr) Formules de protéines de fusion vegfr-fc
MA51291A (fr) Protéines de fusion il-2 fc modifiées
EP3519442A4 (fr) Protéines de fusion immunomodulatrices
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
DK3292141T3 (da) Fusionsproteiner
EP3589662A4 (fr) Protéine monovalente inductible de fixation d' antigène
PT3649151T (pt) Proteínas de suporte
IL254516B (en) Proteins specific for cd137
EP3850007A4 (fr) Protéines bispécifiques modifiées
DK3197453T3 (da) Kimært protein
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
ES1243880Y (es) Cepillo de dientes
IL262776A (en) Humanized anti-il-1r3 antibodies
DK3107562T3 (da) P97-ids-fusionsproteiner
EP3344278A4 (fr) Protéines de fusion immunoglobuline-insuline
EP3531969A4 (fr) Implant de fusion vertébrale
HUE064240T2 (hu) Fehérjetisztítás
EP3481412A4 (fr) Protéines de fusion à demi-vie sérique prolongée
IL270955A (en) Mmp13 binding immunoglobulins
HUE056166T2 (hu) Új rovargátló fehérjék
EP3436049A4 (fr) Protéine 8 de type angiopoïétine (angptl8)
DK3737402T5 (da) Modificeret protein
DK3259358T3 (da) Forøget proteinekspression